Results 161 to 170 of about 20,750 (203)

Response to dabrafenib and trametinib combined with pembrolizumab in an elderly patient with lung adenocarcinoma of unknown primary harboring BRAF V600E mutation and high PD-L1 expression: a case report. [PDF]

Front Immunol
Li N, Hu J, Bao G, Cai Z.
europepmc   +1 more source

Treatment-Related Adverse Events in Individuals with BRAF-Mutant Cutaneous Melanoma Treated with BRAF and MEK Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel)
Belloni S, Virgili R, Caruso R, Arrigoni C, Magon A, Rocco G, De Maria M.   +6 more
europepmc   +1 more source

Dedifferentiation and Redifferentiation of Follicular-Cell-Derived Thyroid Carcinoma: Mechanisms and Therapeutic Implications. [PDF]

Biomedicines
He Y, Tang Z, Xu M, Huang T.
europepmc   +1 more source

Successful treatment of osimertinib-resistant EGFR-mutant NSCLC with acquired BRAF V600E mutation using triple combination therapy: a case report with pathological confirmation. [PDF]

World J Surg Oncol
Lin M, Chen X, Lin F, Yang Y.
europepmc   +1 more source

First-line treatment strategies for <i>BRAF</i>-V600E mutated non-small cell lung cancer: lessons from real-world data and ongoing uncertainties. [PDF]

J Thorac Dis
Zannini I, De Giglio A.
europepmc   +1 more source

Clinical outcomes of dabrafenib plus trametinib in locally advanced or metastatic BRAF V600E-mutant papillary thyroid cancer. [PDF]

Am J Cancer Res
Chen YH, Chou CK, Chi SY, Chang YH, Wang PW, Chan YC.   +5 more
europepmc   +1 more source

Systemic treatment for a young patient with stage IV melanoma: A case report. [PDF]

Oncol Lett
Huang X, Zhao L, Wang P, Xue D.
europepmc   +1 more source

DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth. [PDF]

Nat Cell Biol
Williams AF, Gervasio DAG, Turkal CE, Stuhlfire AE, Wang MX, Mauch BE, Plawat R, Nguyen AH, Paw MH, Hairani M, Lathrop CP, Harris SH, Page JL, Hangauer MJ.   +13 more
europepmc   +1 more source

Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports. [PDF]

Oncologist
He X, Xie S, Jia C, Wu X, Chen Z, Wang T.   +5 more
europepmc   +1 more source

Case Report: pembrolizumab monotherapy achieves durable disease control in a patient with <i>BRAF</i> V600E-mutant advanced lung adenocarcinoma and high PD-L1 expression intolerant to <i>BRAF</i>/<i>MEK</i> inhibition. [PDF]

Front Oncol
Zhao W, Zhou R, Feng C.
europepmc   +1 more source